![](https://library.celltelligence.com/wp-content/uploads/2021/01/Celltelligence-Featured-Images_Daiichi_Gilead.png)
$0
Daiichi Sankyo Authorizes Yescarta’s First Treatment Center in Japan 11 Months After Approval
On Thursday, December 16, Gilead (Kite) announced (press release) that Daiichi Sankyo has authorized Yescarta’s (Gilead’s CD19 CAR-T) first treatment center in Japan. Below, Celltelligence provides insights on how Yescarta’s footprint in Japan may potentially increase Gilead’s (Kite) WW market revenue, while discussing differences in ATC onboarding rates between the US and Japan.